(NASDAQ:EKSO) EKSO BIONICS HOLDINGS, shares are soaring this morning on the FDA news that they are approved to market the Robotic Exoskeleton for use with multiple Sclerosis patients.

Shares are up more than 30% and closing in on 6,500 trades in the morning session. $2.29 a share as of writing this post.

Ekso Bionics Receives FDA Clearance to Market its EksoNR Robotic Exoskeleton for Use with Multiple Sclerosis Patients

First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis

RICHMOND, Calif., June 13, 2022 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for use with Multiple Sclerosis (MS) patients. EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use in patients with MS, an indication which significantly expands the devices use to a broader group of patients.



Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist